Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

9.9K
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.9K
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

3.0K
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
3.0K
Abnormal Proliferation02:23

Abnormal Proliferation

5.0K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Use of a Glycan Library Reveals a New Model for Enteric Virus Oligosaccharide Binding and Virion Stabilization.

Journal of virology·2019
Same author

Hospitalizations for Inflammatory Bowel Disease Among Medicare Fee-for-Service Beneficiaries - United States, 1999-2017.

MMWR. Morbidity and mortality weekly report·2019
Same author

Transforming growth factor-β1-regulated Fas/FasL pathway activation suppresses nucleus pulposus cell apoptosis in an inflammatory environment.

Bioscience reports·2019
Same author

Co-targeting p53-R249S and CDK4 synergistically suppresses survival of hepatocellular carcinoma cells.

Cancer biology & therapy·2019
Same author

RNA-binding motif protein 10 induces apoptosis and suppresses proliferation by activating p53.

Oncogene·2019
Same author

Ubiquitin ligase TRIM71 suppresses ovarian tumorigenesis by degrading mutant p53.

Cell death & disease·2019

Related Experiment Video

Updated: Dec 31, 2025

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay
05:17

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Published on: February 9, 2021

1.9K

Targeting p53-MDM2-MDMX loop for cancer therapy.

Qi Zhang1, Shelya X Zeng, Hua Lu

  • 1Department of Biochemistry & Molecular Biology and Tulane Cancer Center, Tulane University School of Medicine, 1430 Tulane Ave, Louisiana, LA, 70112, USA.

Sub-Cellular Biochemistry
|September 10, 2014
PubMed
Summary

The tumor suppressor p53, crucial for genomic stability, is often inactivated in cancer. Researchers are developing small molecules to target its regulators, MDM2 and MDMX, for novel cancer therapies.

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.7K
Yeast As a Chassis for Developing Functional Assays to Study Human P53
14:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

9.9K

Related Experiment Videos

Last Updated: Dec 31, 2025

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay
05:17

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Published on: February 9, 2021

1.9K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.7K
Yeast As a Chassis for Developing Functional Assays to Study Human P53
14:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

9.9K

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • The tumor suppressor p53 is vital for preventing cancer by maintaining genomic stability.
  • MDM2 and MDMX are key regulators that inactivate p53, and their dysregulation is linked to various human cancers.
  • The p53-MDM2-MDMX feedback loop is critical in the development of tumors with wild-type p53.

Purpose of the Study:

  • To review strategies for discovering selective inhibitors of MDM2.
  • To highlight advanced small molecules targeting the p53-MDM2 interaction in clinical trials.
  • To discuss other therapeutic approaches for the p53-MDM2-MDMX pathway.

Main Methods:

  • Review of literature on screening and discovery of MDM2 inhibitors.
  • Focus on synthetic small molecules interfering with p53-MDM2 interaction.
  • Discussion of therapeutic strategies targeting the p53-MDM2-MDMX loop.

Main Results:

  • Intensive research has focused on identifying small molecules and peptides targeting the p53-MDM2-MDMX pathway.
  • Several advanced synthetic small molecules inhibiting the p53-MDM2 interaction are in Phase I clinical trials.
  • Various strategies targeting this loop show promise for cancer therapy and prevention.

Conclusions:

  • Targeting the p53-MDM2-MDMX pathway offers a promising avenue for cancer treatment.
  • Selective MDM2 inhibitors are advancing through clinical trials.
  • Further exploration of this pathway could lead to improved cancer therapies.